Literature DB >> 29555420

A genetically selected cyclic peptide inhibitor of BCL6 homodimerization.

Eliot L Osher1, Francisco Castillo1, Nagarajan Elumalai1, Michael J Waring2, Garry Pairaudeau3, Ali Tavassoli4.   

Abstract

We report an inhibitor of the homodimeric protein-protein interaction of the BCL6 oncoprotein, identified from a genetically encoded SICLOPPS library of 3.2 million cyclic hexapeptides in combination with a bacterial reverse two-hybrid system. This cyclic peptide is shown to bind the BTB domain of BCL6, disrupts its homodimerization, and subsequent binding of the SMRT2 corepressor peptide.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29555420     DOI: 10.1016/j.bmc.2018.03.012

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.

Authors:  Yong Ai; Lucia Hwang; Alexander D MacKerell; Ari Melnick; Fengtian Xue
Journal:  J Med Chem       Date:  2021-04-12       Impact factor: 7.446

Review 2.  Targeting Transcription Factors for Cancer Treatment.

Authors:  Mélanie Lambert; Samy Jambon; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

Review 3.  Cyclic Peptides: Promising Scaffolds for Biopharmaceuticals.

Authors:  Donghyeok Gang; Do Wook Kim; Hee-Sung Park
Journal:  Genes (Basel)       Date:  2018-11-16       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.